Utah's Office of AI Policy authorized health-tech startup Doctronic to let AI review and approve routine prescription renewals under a one-year regulatory sandbox, with physician sign-off, monthly safety reporting, and early data still under scrutiny.
99.2 %
AI-physician treatment-plan concordance in earlier validation test (500 urgent-care cases)
500 cases
Urgent-care cases in validation test
2 reports
Monthly compliance reports received (as of May 2026)
20–200 non-controlled medications
Formulary size
Details
Maturity
Pilot
Promoter
Utah Office of Artificial Intelligence Policy (Utah Department of Commerce) / Doctronic
Period
Oct 2025 – Oct 2026 (one-year pilot)
Keywords
health, regulation, digital government, AI governance
Context
Utah's Office of Artificial Intelligence Policy (OAIP), acting under statutory authority to grant temporary regulatory relief, authorised health-tech startup Doctronic to test AI-driven prescription renewals. The one-year pilot (October 2025 – October 2026) covers 30-, 60- or 90-day renewals for a formulary of roughly 20–200 non-controlled medications; in Phase 1, every AI-recommended renewal must be reviewed by a licensed physician before it reaches the pharmacy.
Activities
Safeguards include identity verification, hard stops preventing dispensation of controlled substances, escalation protocols routing complex cases to human physicians, a requirement that Doctronic carry medical liability insurance covering AI-related risk, and monthly compliance reporting to OAIP.
Results
As of May 2026, OAIP had reported no serious safety incidents, based on just two monthly compliance reports received so far; a Deseret News article cited an earlier validation test in which Doctronic's recommendations matched physicians' treatment plans in 99.2% of 500 urgent-care cases.
Conclusions
Independent security researchers identified vulnerabilities in the platform (reported via Telehealth.org), and the American Medical Association's CEO publicly warned about accountability risks when AI makes renewal decisions without direct physician involvement. Rigorous measurement of economic and public-health outcomes is not scheduled until later pilot phases.
Implementation
Indicative cost
Low (< €50k) — No budget disclosed; conservative low estimate given the capped formulary and renewal-ceiling scale of the pilot.
Time to results
Short (< 1 year)
Staffing & skills
Utah Office of Artificial Intelligence Policy (OAIP) authorises and monitors the pilot; Doctronic operates the AI system with licensed physicians reviewing every AI-recommended renewal in Phase 1
Conditions for success
Identity verification, hard stops preventing dispensation of controlled substances, and escalation protocols routing complex cases to human physicians
Doctronic required to carry medical liability insurance covering AI-related risk
Monthly compliance reporting to OAIP
Common failure modes
Independent security researchers identified platform vulnerabilities (reported via Telehealth.org)
American Medical Association's CEO publicly warned about accountability risks when AI makes renewal decisions without direct physician involvement
Rigorous measurement of economic and public-health outcomes is not scheduled until later pilot phases
Where it fits
Governance type
state regulatory sandbox
Scale
state (Utah)
Income level
high-income
Commonly funded by
National / regional programmes
Indicative funding routes for practices of this type — always check each programme's current calls and eligibility rules.
Do you run this practice?
Claim it —
verified implementers get a public contact pathway and can propose corrections.
Data sources
Where this practice's information was retrieved from, and when.
The UK's Algorithmic Transparency Recording Standard requires central government bodies to publish structured records of algorithmic tools that significantly influence …